State-of-the-art therapeutic medical countermeasures for viral threat agents

Biosecurity and Bioterrorism

Volumn 9, Issue 4, 2011, Pages 351-360

  Sampath, Aruna ^a   Metz, Matthew ^b   Stundick, Melissa ^b   Larsen, Joseph C ^b  

^a SAIC FREDERICK INC   (United States)

^b Office of the Assistant Secretary for Preparedness and Response   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ANIMAL; BIOLOGICAL WARFARE; DISASTER PLANNING; DISEASE TRANSMISSION; HUMAN; IMMUNOTHERAPY; METHODOLOGY; ORGANIZATION AND MANAGEMENT; REVIEW; VIRUS INFECTION;

ANIMALS; ANTIVIRAL AGENTS; BIOTERRORISM; DISASTER PLANNING; HUMANS; IMMUNOTHERAPY; VIRUS DISEASES;

EID: 82655189182     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2011.0047     Document Type: Review

References (57)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22(2):151-185. (Pubitemid 36279392)
2. U. S. Food and Drug Administration. Guidance for Industry: Animal Models-Essential Elements to Address Efficacy Under the Animal Rule. January 2009. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm078923.pdf. Accessed September 7, 2011.
3. Jahrling PB, Fritz EA, Hensley LE. Countermeasures to the bioterrorist threat of smallpox. Curr Mol Med 2005;5(8):817-826. (Pubitemid 43009520)
4. Bray M, Pilch R. Filoviruses: recent advances and future challenges. Expert Rev Anti Infect Ther 2006;4(6):917-921. (Pubitemid 46040343)
5. Olinger GG, Biggins JE, Melanson VR, Wahl-Jensen V, Geisbert TW, Hensley LE. Drug targets in infections with Ebola and Marburg viruses. Infect Disord Drug Targets 2009;9(2):191-200.
6. Steele KE, Twenhafel NA. Review paper: pathology of animal models of alphavirus encephalitis. Vet Pathol 2010;47(5):790-805.
7. Yang G, Pevear DC, Davies MH, et al. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J Virol 2005;79(20):13139-13149. (Pubitemid 41433232)
8. Quenelle DC, Buller RM, Parker S, et al. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother 2007;51(2):689-695. (Pubitemid 46185291)
9. Nalca A, Hatkin JM, Garza NL, et al. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir Res 2008;79(2):121-127.
10. Huggins J, Goff A, Hensley L, et al. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob Agents Chemother 2009;53(6):2620-2625.
11. SIGA Technologies Inc. Safety, tolerability, pharmacokinetics (PK) of the anti-orthopox drug, ST-246 (246-Safety). ClinicalTrials.gov 2000. NLM Identifier NCT00907803. http://clinicaltrials.gov/ct2/show/NCT00907803?term= NCT00907803&rank=1. Accessed September 7, 2011.
12. Jordan R, Chinsangaram J, Bolken TC, et al. Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob Agents Chemother 2010;54(6):2560-2566.
13. Stittelaar KJ, Neyts J, Naesens L, et al. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox viral infection. Nature 2006;439(7077):745-748. (Pubitemid 43237623)
14. Dropulic LK, Cohen JI. Update on new antivirals under development for the treatment of double-stranded DNA virus infections. Clin Pharmacol Ther 2010;88(5):610-619.
15. Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropylcidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci U S A 2008;105(20):7293-7297. (Pubitemid 351754471)
16. Rice AD, Adams MM, Lampert B, et al. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2011;3(2):63-82.
17. Rice AD, Adams MM, Wallace G, et al. Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans. Viruses 2011;3(1):47-62.
18. Chimerix Inc. Comparative bioavailability and effect of food on CMX001 in healthy volunteers. ClinicalTrials.gov 2000. NLM Identifier NCT00780182. http://clinicaltrials.gov/ct2/show/NCT00780182?term=chimerix&rank=5. Accessed September 7, 2011.
19. Myskiw C, Piper J, Huzarewich R, Booth TF, Cao J, He R. Nigericin is a potent inhibitor of the early stage of vaccinia virus replication. Antivir Res 2010;88(3):304-310.
20. Howell MD, Streib JE, Kim BE, et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol 2009;129(11):2668- 2675.
21. Dawson RM, Liu CQ. Properties and applications of antimicrobial peptides in biodefense against biological warfare threat agents. Crit Rev Microbiol 2008;34(2):89-107. (Pubitemid 351878991)
22. Alkhalil A, Strand S, Mucker E, Huggins JW, Jahrling PB, Ibrahim SM. Inhibition of monkeypox virus replication by RNA interference. Virol J 2009;6:188.
23. Ahmed CM, Martin JP, Johnson HM. IFN mimetic as a therapeutic for lethal vaccinia virus infection: possible effects on innate and adaptive immune responses. J Immunol 2007;178(7):4576-4583. (Pubitemid 46492410)
24. Ahmed CM, Dabelic R, Waiboci LW, Jager JD, Heron LL, Johnson HM. SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 2009;83(3):1402-1415.
25. McCausland MM, Benhnia MR, Crickard L, et al. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir Ther 2010;15(4):661-675.
26. Tomimori Y, Kawakami Y, McCausland, MM, et al. Protective murine and human monoclonal antibodies against eczema vaccinatum. Antivir Ther 2011;16:67-75.
27. Zaitseva M, Kapnick SM, Meseda CA, et al. Passive immunotherapies protect WRvFire and IHD-J-Luc vaccinia virus-infected mice from lethality by reducing viral loads in the upper respiratory tract and internal organs. J Virol 2011;85(17):9147-9158.
28. Guo H, Pan X, Mao R, et al. Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses. Antimicrob Agents Chemother 2011;55(2):478-486.
29. Panchal RG, Kota KP, Spurgers KB, et al. Development of high-content imaging assays for lethal viral pathogens. J Biomol Screen 2010;15(7):755-765.
30. Wolf MC, Freiberg AN, Zhang T, et al. A broad spectrum antiviral targeting entry of enveloped viruses. Proc Natl Acad Sci U S A 2010;107(7):3157-3162.
31. Francis J, Kalina W, Warren T, et al. The discovery and efficacy of a small molecule inhibitor of Ebola capsid assembly in an animal model. 2010; Abstract 123. 23rd ICAR, San Francisco, California.
32. Aman MJ, Kinch MS, Warfield K, et al. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res 2009;83(3):245-251.
33. Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. Lancet 2003;362(9400):1953-1958. (Pubitemid 37548417)
34. Connor JH, McKenzie MO, Parks GD, Lyles DS. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses. Virology 2007;362(1):109-119. (Pubitemid 46617696)
35. Smith DR, McCarthy S, Chrovian A, et al. Inhibition of heat-shock protein 90 reduces Ebola virus replication. Antiviral Res 2010;87(2):187-194.
36. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med 2010;16(9):991-994.
37. Geisbert TW, Hensley LE, Kagan E, et al. Postexposure protection of guinea pigs against a lethal Ebola virus challenge is conferred by RNA interference. J Infect Dis 2006;193(12):1650-1657. (Pubitemid 43839469)
38. Geisbert TW, Lee AC, Robbins M, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375(9729):1896-1905.
39. Michelow IC, Lear C, Scully C, et al. High-dose mannose binding lectin therapy for Ebola virus infection. J Infec Dis 2011;203(2):175-179.
40. Hensley LE, Stevens EL, Yan SB, et al. Recombinant human activated protein C for the postexposure treatment of Ebola hemorrhagic fever. J Infect Dis 2007;196 Suppl 2:S390-399. (Pubitemid 351417286)
41. Wauquier N, Becquart P, Gasquet C, Leroy EM. Immunoglobulin G in Ebola outbreak survivors, Gabon. Emerg Infect Dis 2009;15(7):1136-1137.
42. Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM. Human fatal Zaire Ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis. PLoS Negl Trop Dis 2010;4(10):e837.
43. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre-and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002;76(12):6408-6412. (Pubitemid 34556338)
44. Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine 2007;25(6):993-999. (Pubitemid 44937459)
45. Oswald WB, Geisbert TW, Davis KJ, et al. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007;3(1):62-66.
46. Shedlock DJ, Bailey MA, Popernack PM, Cunningham JM, Burton DR, Sullivan NJ. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology 2010;401(2):28-35.
47. Reichert E, Clase A, Bacetty A, Larsen J. Alphavirus antiviral drug development: scientific gap analysis and prospective research areas. Biosecur Bioterror 2009;7(4):413-427.
48. Julander JG, Bowen RA, Rao JR, et al. Treatment of Venezuelan equine encephalitis virus infection with (-)-carbodine. Antiviral Res 2008;80(3):309-315.
49. O'Brien L. Inhibition of multiple strains of Venezuelan equine encephalitis virus by a pool of four short interfering RNAs. Antivir Res 2007;75(1):20-29. (Pubitemid 46613790)
50. Paessler S, Rijnbrand R, Stein DA, et al. Inhibition of alphavirus infection in cell culture and in mice with antisense morpholino oligomers. Virology 2008;376(2):357-370.
51. Parker MD, Buckley MJ, Melanson VR, Glass PJ, Norwood D, Hart MK. Antibody to the E3 glycoprotein protects mice against lethal Venezuelan equine encephalitis virus infection. J Virol 2010;84(24):12683-12690.
52. Hu WG, Phelps AL, Jager S, et al. A recombinant humanized monoclonal antibody completely protects mice against lethal challenge with Venezuelan equine encephalitis virus. Vaccine 2010;28(34):5558-5564.
53. Goodchild SA, O'Brien LM, Steven J, et al. A humanized murine monoclonal antibody with broad serogroup specificity protects mice from challenge with Venezuelan equine encephalitis virus. Antiviral Res 2011;90(1):1-8.
54. Hunt AR, Frederickson S, Maruyama T, Roehrig JT, Blair CD. The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity. PLoS Negl Trop Dis 2010;4(7):e739.
55. Hunt AR, Bowen RA, Frederickson S, Roehrig JT, Blair CD. Treatment of mice with human monoclonal antibody 24h after lethal aerosol challenge with virulent Venezuelan equine encephalitis virus prevents disease but not infection. Virology 2011;414(2):146-152.
56. Logue CH, Phillips AT, Mossel EC, et al. Treatment with cationic liposome-DNA complexes (CLDCs) protects mice from lethal Western equine encephalitis virus (WEEV) challenge. Antiviral Res 2010;87(2):195-203.
57. Jordan R, Hruby D. Smallpox antiviral drug development: satisfying the animal efficacy rule. Expert Rev Anti Infect Ther 2006; (2):277-289.